论文部分内容阅读
目的探讨血清可溶性CDl05(sCDl05)、基质金属蛋白酶-9(MMP-9)与冠状动脉粥样硬化斑块稳定性的关系。方法 150例研究对象分成急性冠状动脉综合征(ACS)组60例、稳定性心绞痛(SAP)组60例、对照组30例。采用酶联免疫吸附法检测sCDl05和MMP-9。通过冠状动脉造影计算冠状动脉病变狭窄形态积分,并与血清sCDl05,MMP-9水平进行相关分析。结果 ACS组sCDl05、MMP-9水平显著高于SAP组和对照组(t1=2.362,t2=2.875,P均<0.05),SAP组与对照组间差异无统计学意义(t=1.688,P>0.05);ACS组冠状动脉狭窄病变形态积分明显高于SAP组(t=2.164,P<0.05)。相关分析显示,血清sCDl05及MMP-9水平均与冠状动脉造影狭窄病变形态积分呈正相关(r1=0.60,r2=0.54,均P<0.01);sCDl05与MMP-9呈显著正相关(r=0.82,P<0.01)。结论冠心病患者血清sCDl05水平升高提示动脉粥样硬化斑块不稳定;联合检测血清sCDl05、MMP-9有助于预测ACS的发生。
Objective To investigate the relationship between serum soluble CD105 (sCDl05), matrix metalloproteinase-9 (MMP-9) and coronary atherosclerotic plaque stability. Methods 150 cases were divided into 60 cases of acute coronary syndrome (ACS) group, 60 cases of stable angina pectoris (SAP) group and 30 cases of control group. The sCD105 and MMP-9 were detected by enzyme-linked immunosorbent assay. Coronary artery stenosis was calculated by coronary angiography, and correlated with serum sCD105, MMP-9 levels. Results The levels of sCD105 and MMP-9 in ACS group were significantly higher than those in SAP group and control group (t1 = 2.362, t2 = 2.875, P <0.05). There was no significant difference between SAP group and control group (t = 1.688, P> 0.05). The score of coronary artery stenosis in ACS group was significantly higher than that in SAP group (t = 2.164, P <0.05). Correlation analysis showed that serum sCD105 and MMP-9 levels were positively correlated with coronary angiography stenosis (r1 = 0.60, r2 = 0.54, all P <0.01); sCD105 was positively correlated with MMP-9 , P <0.01). Conclusion The serum level of sCD105 in patients with coronary heart disease (CAD) suggests that atherosclerotic plaque is unstable. Combined detection of serum sCD105 and MMP-9 may be useful in predicting the occurrence of ACS.